open access

Vol 73, Supp. II (2015)
Reviews
Published online: 2015-03-06
Submitted: 2015-03-06
Accepted: 2015-03-06
Get Citation

The efficacy and safety of rivaroxaban in patients with atrial fibrillation undergoing elective cardioversion — the results of X-VeRT trial

Marcin Barylski
DOI: 10.5603/KP.2015.0031

open access

Vol 73, Supp. II (2015)
Reviews
Published online: 2015-03-06
Submitted: 2015-03-06
Accepted: 2015-03-06

Abstract

X-VeRT trial is the first prospective randomised trial evaluating the efficacy and safety of a novel oral anticoagulant — rivaroxa­ban — compared with vitamin K antagonist therapy in patients undergoing elective cardioversion. The study showed a similar risk of the primary endpoint in both groups, both in terms of efficacy and safety. However, rivaroxaban was associated with significantly shorter time to cardioversion compared with vitamin K antagonists (p < 0.001). Based on data from X-VeRT trial, rivaroxaban can be regarded as an effective and safe alternative to vitamin K antagonists in patients with atrial fibrillation scheduled for cardioversion, regardless of strategy type.

Abstract

X-VeRT trial is the first prospective randomised trial evaluating the efficacy and safety of a novel oral anticoagulant — rivaroxa­ban — compared with vitamin K antagonist therapy in patients undergoing elective cardioversion. The study showed a similar risk of the primary endpoint in both groups, both in terms of efficacy and safety. However, rivaroxaban was associated with significantly shorter time to cardioversion compared with vitamin K antagonists (p < 0.001). Based on data from X-VeRT trial, rivaroxaban can be regarded as an effective and safe alternative to vitamin K antagonists in patients with atrial fibrillation scheduled for cardioversion, regardless of strategy type.

Get Citation

Keywords

cardioversion, oral anticoagulant, rivaroxaban

About this article
Title

The efficacy and safety of rivaroxaban in patients with atrial fibrillation undergoing elective cardioversion — the results of X-VeRT trial

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 73, Supp. II (2015)

Pages

11-18

Published online

2015-03-06

DOI

10.5603/KP.2015.0031

Keywords

cardioversion
oral anticoagulant
rivaroxaban

Authors

Marcin Barylski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl